Paul Josephs bought $98k of LFCR
Chief Executive Officer at LIFECORE BIOMEDICAL, INC. \DE\. 17,000 shares at an average of $5.74, traded Jan 8, 2025, filed Jan 8, 2025.
Score components
- +25RoleCEO
- +10Trade size$98k at market
- 0Relative to holdingsHoldings up 3.1%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-000943, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 8, 2025 | POpen-market purchase Common Stock | +17,000 | $5.74 | $98k | 559,717 | Jan 8, 2025 |
Related signals
Other insiders at LIFECORE BIOMEDICAL, INC. \DE\ and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | LFCRsell LIFECORE BIOMEDICAL, INC. \DE\ | Aron R. English owner | $9.1M 1,386,060 shares | -84% | |
| 21Weak | LFCRsell LIFECORE BIOMEDICAL, INC. \DE\ | Aron R. English owner | $86k 12,334 shares | -1% | |
| 27Weak | LFCRsell LIFECORE BIOMEDICAL, INC. \DE\ | Aron R. English owner | $362k 51,496 shares | -3% | |
| 26Weak | LFCRsell LIFECORE BIOMEDICAL, INC. \DE\ | Aron R. English owner | $290k 41,091 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.